Leap Therapeutics

US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) had declined to exercise its option to take up development and commercial rights in Asia for DKN-01, Leap’s anti-Dickkopf-1 (DKK1) monoclonal antibody (mAb). Despite this decision, the two companies will continue…